BR112014019052A8 - Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer - Google Patents

Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer

Info

Publication number
BR112014019052A8
BR112014019052A8 BR112014019052A BR112014019052A BR112014019052A8 BR 112014019052 A8 BR112014019052 A8 BR 112014019052A8 BR 112014019052 A BR112014019052 A BR 112014019052A BR 112014019052 A BR112014019052 A BR 112014019052A BR 112014019052 A8 BR112014019052 A8 BR 112014019052A8
Authority
BR
Brazil
Prior art keywords
methods
cancer
cdk8
antimetastatic
cdki
Prior art date
Application number
BR112014019052A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014019052A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
B Robinson Igor
C Porter Donald
P Wentland Mark
Original Assignee
Senex Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senex Biotechnology Inc filed Critical Senex Biotechnology Inc
Publication of BR112014019052A2 publication Critical patent/BR112014019052A2/pt
Publication of BR112014019052A8 publication Critical patent/BR112014019052A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
BR112014019052A 2012-02-02 2013-02-01 Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer BR112014019052A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594023P 2012-02-02 2012-02-02
US201261673419P 2012-07-19 2012-07-19
PCT/US2013/024515 WO2013116786A1 (en) 2012-02-02 2013-02-01 Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer

Publications (2)

Publication Number Publication Date
BR112014019052A2 BR112014019052A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
BR112014019052A8 true BR112014019052A8 (pt) 2017-07-11

Family

ID=47716178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019052A BR112014019052A8 (pt) 2012-02-02 2013-02-01 Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer

Country Status (16)

Country Link
US (2) US9321737B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2809324B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6193268B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150023223A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104363913B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013214783B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014019052A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014002062A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7151516A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA032429B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP201706688B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY165446A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014501862A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201404596UA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA117342C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013116786A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703851A (en) * 2012-07-27 2017-01-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents
HK1206741A1 (en) * 2012-08-23 2016-01-15 霍夫曼-拉罗奇有限公司 Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
KR20160014568A (ko) 2012-11-01 2016-02-11 유니버시티 오브 싸우스 캐롤라이나 전립선암을 치료하는 방법
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
AU2014369834B2 (en) 2013-12-24 2018-12-20 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US9957251B2 (en) 2014-04-18 2018-05-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2015296968A1 (en) * 2014-06-10 2017-02-02 University Of South Carolina Methods and compositions for treatment of HER-positive cancers
WO2016100782A1 (en) 2014-12-18 2016-06-23 University Of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
KR20180003597A (ko) * 2015-05-08 2018-01-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유도체로의 치료를 위한 환자의 표적화된 선택
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3370720A1 (en) * 2015-11-03 2018-09-12 Lu License AB Compounds for treatment of hypoproliferative disorders
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
WO2017164230A1 (ja) * 2016-03-23 2017-09-28 国立大学法人 岡山大学 リン酸化ｓａｒｍ１、抗体、ｓａｒｍ１リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、ｓａｒｍ１改変体及び使用
WO2018027082A1 (en) 2016-08-03 2018-02-08 The Broad Institute, Inc. Use of cdk8 inhibitors to treat diseases of inflammation and autoimmunity
US11578067B2 (en) * 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
WO2018151633A1 (ru) * 2017-02-20 2018-08-23 Закрытое Акционерное Общество "Биокад" Способы получения производных 4-(((нафталин-2-ил)алкил)амино)хинозалин-6-карбонитрилов
WO2018156858A1 (en) * 2017-02-23 2018-08-30 University Of South Carolina Use of cdk8/19 inhibitors for treatment of established colon cancer hepatic metastasis
EP3591040A4 (en) 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
US11013728B2 (en) 2017-04-03 2021-05-25 Kyoto Pharmaceutical Industries, Ltd. Cyclin-dependent kinase 8 and/or 19 inhibitor
RU2641001C1 (ru) * 2017-04-03 2018-01-15 Закрытое Акционерное Общество "Биокад" Соли 4-((2-(6-(4-метилпиперазин-1-карбонил)нафталин-2-ил)этил)амино)хиназолин-6-карбонитрила и фармацевтическая композиция
CN111278469A (zh) * 2017-09-18 2020-06-12 陈扎克伯格生物中心公司 用于治疗三阴性乳腺癌的方法
EP3691642B1 (en) 2017-10-02 2024-03-06 Boehringer Ingelheim International GmbH [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
US12281080B2 (en) 2018-08-21 2025-04-22 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
CN113677341B (zh) 2019-02-01 2024-07-05 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
EP4249587A4 (en) 2020-11-20 2025-02-19 Orizuru Therapeutics, Inc. RIPENING AGENT
CA3208794A1 (en) 2021-02-09 2022-08-18 Orizuru Therapeutics, Inc. Maturation agent
CA3214794A1 (en) * 2021-03-25 2022-09-29 University Of South Carolina Cdk8/19 inhibitors for the treatment of cytokine storm
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
WO2023095801A1 (ja) 2021-11-24 2023-06-01 レグセル株式会社 ヒト誘導性制御性ｔ細胞およびその作製方法
TW202334397A (zh) 2021-11-24 2023-09-01 日商雷格細胞股份有限公司 用於治療或預防t細胞相關疾病之醫藥組合物
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
JPWO2023210578A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-04-25 2023-11-02
KR20250036837A (ko) 2022-07-14 2025-03-14 오리즈루 세라퓨틱스 가부시키가이샤 세포 이식용의 피브린 겔 시트
KR20250077533A (ko) 2022-09-26 2025-05-30 고쿠리츠 다이가쿠 호진 교토 다이가쿠 T 세포 제조 방법
CN119948155A (zh) 2022-09-26 2025-05-06 雷格细胞股份有限公司 含有嵌合抗原受体（car）的诱导性调节性t细胞
WO2024166969A1 (ja) 2023-02-08 2024-08-15 レグセル株式会社 天疱瘡を治療または予防するための医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
JP2004500304A (ja) * 1997-10-27 2004-01-08 アグロン　ファ−マシュ−テイカルズ　インコ−ポレイテッド ４−アミノチアゾ−ル誘導体、その製造法およびサイクリン依存キナ−ゼ抑制剤としての使用法
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
US20040180844A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
MXPA05010824A (es) 2003-04-10 2005-12-05 Pfizer Compuestos biciclicos como antagonistas del receptor nr2b.
EP2021019A4 (en) * 2006-05-15 2009-12-09 Senex Biotechnology Inc IDENTIFICATION OF CDKI PATH HAZARD
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof

Also Published As

Publication number Publication date
CN104363913A (zh) 2015-02-18
EP3431087A1 (en) 2019-01-23
MY165446A (en) 2018-03-22
CL2014002062A1 (es) 2015-03-20
AU2013214783B2 (en) 2017-07-06
EP2809324B1 (en) 2018-08-01
SG11201404596UA (en) 2014-10-30
BR112014019052A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
GEP201706688B (en) 2017-06-26
US20170071942A1 (en) 2017-03-16
UA117342C2 (uk) 2018-07-25
EA201491399A1 (ru) 2015-04-30
EA032429B1 (ru) 2019-05-31
WO2013116786A1 (en) 2013-08-08
EA028595B1 (ru) 2017-12-29
EP2809324A1 (en) 2014-12-10
EA201791284A1 (ru) 2017-10-31
US9321737B2 (en) 2016-04-26
PH12014501862A1 (en) 2014-11-24
AU2013214783A1 (en) 2014-08-28
US10993945B2 (en) 2021-05-04
US20140038958A1 (en) 2014-02-06
JP2015506376A (ja) 2015-03-02
CN104363913B (zh) 2018-08-21
JP6193268B2 (ja) 2017-09-06
CO7151516A2 (es) 2014-12-29
KR20150023223A (ko) 2015-03-05

Similar Documents

Publication Publication Date Title
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
BR112015027951A8 (pt) arilquinazolinas, seus usos, medicamento, composição farmacêutica, e kit
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112014029851A2 (pt) composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
MX2015012526A (es) Inhibodores macrociclicos de cinasa rip2.
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
MX376087B (es) Inhibidores macrocíclicos de cinasa rip2.
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos
BR112019008516A2 (pt) derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements